From 'Lost Cause' to Gold Rush: Biotech Companies Race to Cure AATD

Biotech companies are intensifying their efforts to develop treatments and cures for alpha-1 antitrypsin deficiency (AATD), a rare genetic lung disease that was previously considered untreatable. This surge in research interest has sparked fierce competition marked by patent disputes, startup defections, arbitration cases, and increasing rivalry between U.S. and Chinese biotechnology firms. AATD, which causes progressive lung damage and can lead to early-onset emphysema and COPD, affects thousands of patients worldwide who previously had limited therapeutic options. The growing investment signals a major shift in how the medical industry views this condition, offering new hope for patients diagnosed with this historically neglected disease.